Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Mr Lorenzo was promoting a debenture offering in Waste2Energy Holdings Inc — a now-bankrupt company which was claiming it had technology that converted waste into clean energy....
...The Frenchman was recruited from Roche in 2012 to replace David Brennan, who was ousted amid investor concern over the company’s rapidly deteriorating outlook....
...chief executive, has been credited with strengthening R&D, many of the company’s most promising new drugs stem from Medimmune, the US biotech company acquired in 2007 for £16bn by his predecessor, David Brennan...
...When Mr Soriot replaced David Brennan in 2012, AstraZeneca was considered the laggard among European drugmakers with a failing pipeline and patent losses looming on some of its biggest products....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Pascal Soriot, the former Roche executive who took over as chief executive from the ousted David Brennan in 2012, has sharpened the company’s focus on core areas including cancer, diabetes and respiratory...
...Simon Lowth, who took over as interim chief executive after the abrupt departure of David Brennan last spring and was another frontrunner to run the company permanently, retains his post as chief financial...
...CEOs more typically last four or five years under the increasingly aggressive investor pressure that led to recent departures, such as those of Jeff Kindler at Pfizer and David Brennan at AstraZeneca....
...To be fair to McCain, he has actually been very principled in his opposition to torture – so perhaps the debate is better phrased as libertarians v neocons; or isolationists v interventionists....
...Earnings were boosted by a one-off upfront payment from transferring rights to over-the-counter sales of its heartburn drug Nexium to Pfizer....
...Last month, David Brennan, its chief executive, stepped down....
...Patents on heart blockbusters such as Pfizer’s Lipitor and Sanofi’s Plavix are expiring with little sign that the industry can replicate them....
...Pfizer this week was among the companies to report a drop in first-quarter sales and earnings as generic rivals diluted its sales of Lipitor, the cholesterol-lowering drug that was itself the world’s top...
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Sales of Crestor have slowed this year, while generic versions of Lipitor, a competitor drug produced by Pfizer, are due to go on sale soon....
...David Brennan, chief executive of AstraZeneca, said: “Martin’s appointment to this new role will provide a single point of senior accountability as we continue to make the changes necessary to improve the...
...David Brennan, chief executive, said: “We are pleased with the court’s decision upholding the validity and enforceability of the … patent....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...AstraZeneca is now also mirroring decisions at GSK, Merck, Sanofi-Aventis and Pfizer to “externalise” from predominantly in-house projects to those developed in partnership with other companies and academics...
...David Brennan, chief executive of AstraZeneca, says: “You still need to have sufficient in-house staff to scrutinise external projects.”...
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
International Edition